Malignant bladder tumors account for the 8th among male patients and the 18th among female patients in the structure of tumor diseases. In terms of absolute growth rate, bladder cancer ranks fourth among tumor diseases (the top three are: prostate cancer, kidney cancer and testicular cancer). Multiple and frequent recurrences are characteristic of bladder tumors.

In all countries, most cases (90-95%) of bladder tumors are morphologically transient cell carcinomas; the remaining cases are associated with squamous cell carcinoma and adenocarcinoma. Non-epithelial tumors account for less than 1%.

The main and most reliable method of bladder cancer diagnosis in clinical practice remains cystoscopy with collection of cytological or histological material. But this method does not allow estimation of the depth of tumor invasion into the bladder wall. The depth of invasion is one of the important factors in the choice of surgical treatment: if the muscularis parieta is involved, transurethral resection is not possible (T2 category). In the case of infiltration of surrounding cellular tissue and tumor spread to adjacent organs (T3-T4), the risk of regional lymphadenopathy increases: it occurs in 30% of T2 stages and reaches 65% of T4 stages.

In recent years, computed tomography, magnetic resonance tomography, and transurethral ultrasonography have been used mainly as corrective diagnostic methods to determine the depth of bladder tumor invasion. Based on information provided by Nesterova V. and others, the approach of the recent NLS study using the Metapathia GR hunter may become crucial in determining the prevalence of bladder cancer and in case surveillance. The method's usability, painlessness, and absence of radiation exposure allow multiple studies to be performed while performing case surveillance.